FibroBiologics receives Nasdaq bid price deficiency notice; 180 days to cure

FibroBiologics, Inc.

Nasdaq notified FibroBiologics on July 1, 2025 that common stock closing bid price was below $1.00 for 30 consecutive trading days.
Company has until December 29, 2025 to regain compliance by maintaining $1.00+ closing bid for 10 consecutive business days.
If not cured by deadline, FibroBiologics may qualify for a second 180-day period subject to meeting other listing standards.
Failure to cure could lead to delisting; Company may consider options to regain compliance, no guarantee of success.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.